New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo

Nature Medicine

Volumn 20, Issue 4, 2014, Pages 425-429

  Bullen, C Korin ^a   Laird, Gregory M ^a   Durand, Christine M ^a   Siliciano, Janet D ^a   Siliciano, Robert F ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRYOSTATIN 1; DISULFIRAM; MESSENGER RNA; PANOBINOSTAT; ROMIDEPSIN; TRIPHENYLTETRAZOLIUM; VORINOSTAT;

ARTICLE; ASSAY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VIVO STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; VIRAL OUTGROWTH ASSAY; VIRUS LATENCY; VIRUS RELEASE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; AZEPINES; BRYOSTATINS; CD4-POSITIVE T-LYMPHOCYTES; DEPSIPEPTIDES; DISULFIRAM; HISTONE DEACETYLASE INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; HYDROXAMIC ACIDS; INDOLES; IONOMYCIN; LYMPHOCYTE ACTIVATION; NUCLEAR PROTEINS; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION FACTORS; TRIAZOLES; VIRUS LATENCY;

EID: 84898423894     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3489     Document Type: Article

References (37)

1. Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295-1300 (1997).
2. Wong, J.K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291-1295 (1997).
3. Chun, T.W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94, 13193-13197 (1997).
4. Siliciano, J.D. et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9, 727-728 (2003).
5. Strain, M.C. et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc. Natl. Acad. Sci. USA 100, 4819-4824 (2003).
6. Richman, D.D. et al. The challenge of finding a cure for HIV infection. Science 323, 1304-1307 (2009).
7. Deeks, S.G. et al. Towards an HIV cure: a global scientific strategy. Nat. Rev. Immunol. 12, 607-614 (2012).
8. Karn, J. The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit. Curr. Opin. HIV AIDS 6, 4-11 (2011).
9. Choudhary, S.K. & Margolis, D.M. Curing HIV: pharmacologic approaches to target HIV-1 latency. Annu. Rev. Pharmacol. Toxicol. 51, 397-418 (2011).
10. Hakre, S., Chavez, L., Shirakawa, K. & Verdin, E. HIV latency: experimental systems and molecular models. FEMS Microbiol. Rev. 36, 706-716 (2012).
11. Archin, N.M. et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses 25, 207-212 (2009).
12. Bartholomeeusen, K., Fujinaga, K., Xiang, Y. & Peterlin, B.M. Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription. J. Biol. Chem. 288, 14400-14407 (2013).
13. Contreras, X. et al. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J. Biol. Chem. 284, 6782-6789 (2009).
14. Shirakawa, K., Chavez, L., Hakre, S., Calvanese, V. & Verdin, E. Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol. 21, 277-285 (2013).
15. Doyon, G., Zerbato, J., Mellors, J.W. & Sluis-Cremer, N. Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog. AIDS 27, F7-F11 (2013).
16. Xing, S. et al. Disulfiram reactivates latent HIV-1 in a BCL-2-transduced primary CD4+ T cell model without inducing global T cell activation. J. Virol. 85, 6060-6064 (2011).
17. Banerjee, C. et al. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J. Leukoc. Biol. 92, 1147-1154 (2012).
18. Boehm, D. et al. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle 12, 452-462 (2013).
19. Li, Z., Guo, J., Wu, Y. & Zhou, Q. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res. 41, 277-287 (2013).
20. Zhu, J. et al. Reactivation of latent HIV-1 by inhibition of BRD4. Cell Reports 2, 807-816 (2012).
21. Korin, Y.D., Brooks, D.G., Brown, S., Korotzer, A. & Zack, J.A. Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J. Virol. 76, 8118-8123 (2002).
22. Kulkosky, J. et al. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98, 3006-3015 (2001).
23. Williams, S.A. et al. Prostratin antagonizes HIV latency by activating NF-κB. J. Biol. Chem. 279, 42008-42017 (2004).
24. DeChristopher, B.A. et al. Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nat. Chem. 4, 705-710 (2012).
25. Kinter, A.L., Poli, G., Maury, W., Folks, T.M. & Fauci, A.S. Direct and cytokine-mediated activation of protein kinase C induces human immunodeficiency virus expression in chronically infected promonocytic cells. J. Virol. 64, 4306-4312 (1990).
26. Mehla, R. et al. Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS ONE 5, e11160 (2010).
27. Archin, N.M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482-485 (2012).
28. Blazkova, J. et al. Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4+ T cells from infected individuals receiving effective antiretroviral therapy. J. Infect. Dis. 206, 765-769 (2012).
29. Rasmussen, T.A., Tolstrup, M., Winckelmann, A., Ostergaard, L. & Sogaard, O.S. Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials. Hum. Vacc. Immunother. 9, 790-799 (2013).
30. Spivak, A.M. et al. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin. Infect. Dis. doi:10.1093/cid/cit813 (12 December 2013).
31. Moriuchi, H., Moriuchi, M. & Fauci, A.S. Induction of HIV replication by allogeneic stimulation. J. Immunol. 162, 7543-7548 (1999).
32. Laird, G.M. et al. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog. 9, e1003398 (2013).
33. Han, Y. et al. Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J. Virol. 78, 6122-6133 (2004).
34. Schröder, A.R. et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110, 521-529 (2002).
35. Baba, M., Miyake, H., Okamoto, M., Iizawa, Y. & Okonogi, K. Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV type 1. AIDS Res. Hum. Retroviruses 16, 935-941 (2000).
36. Yang, H.C. et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J. Clin. Invest. 119, 3473-3486 (2009).
37. Shan, L. et al. A novel PCR assay for quantification of HIV-1 RNA. J. Virol. 87, 6521-6525 (2013).